BUSINESS
ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
ASKA Pharmaceutical said on January 14 that it has entered into an option agreement with a biotech originated from Kyoto University, KinoPharma, for an exclusive license to develop and commercialize the biotech’s investigational cervical dysplasia compound. Under the terms of…
To read the full story
Related Article
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





